Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Protecting the thymus may improve lung cancer treatment outcomes

Building on recent discoveries about the adult thymus, Mass General Brigham investigators used artificial intelligence to show that incidental radiation exposure to the thymus may influence outcomes in patients with lung cancer.

25 Aug 2026

Study links thymus radiation to worse lung cancer outcomes

Until recently, the thymus was thought to be of little use beyond puberty, but new research has shown that radiation to the organ is associated with worse outcomes in patients being treated for non-small cell lung cancer (NSCLC).

25 Aug 2026

SBRT improves bowel health related quality-of-life in patients with localized intermediate-risk prostate cancer

Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized intermediate risk prostate cancer indicate that the use of SBRT improved bowel health related quality of life (HRQOL) in this patient population.

25 Aug 2026

Gene removal makes engineered immune cells more effective against osteosarcoma

Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma.

25 Aug 2026

Study maps rising lifetime risk of digestive cancers in China

The global landscape of oncology is shifting, and nowhere is this transition more complex or consequential than in China.

24 Aug 2026

Antibodies for visualizing cell identity and tumor architecture

Whether you are characterizing cell state transitions, assessing organelle integrity, or building a multiplex immunofluorescence (IF) assay, you need reliable structural markers for your imaging.

From Antibodies Incorporated 21 Aug 2026

Younger lung cancer patients show more targetable gene alterations

Younger adults with non-small cell lung cancer are significantly more likely than older patients to have genetic alterations that can be matched with targeted therapies, according to a large international study led in part by researchers at Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine.

21 Aug 2026

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

Only three of 1,357 FDA-cleared AI devices tested patient outcomes

Researchers found that among 1,357 FDA-cleared or approved AI/ML-enabled medical devices, only 34 were linked to registered clinical trials and just three had been evaluated for patient-centered outcomes. The study highlights major gaps in prospective testing, demographic representation, transparency, and evidence showing whether medical AI meaningfully improves patients’ health.

20 Aug 2026

Federal and industry sponsors play complementary roles in cancer clinical trials

A comparative study of the cancer clinical trial portfolios supported by federal funding versus industry funding reveals they have distinct, interdependent roles in cancer research.

20 Aug 2026

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The ELRIG Mid-Career Initiative supports scientists in drug discovery, addressing unique challenges and fostering leadership development for career transitions.

20 Aug 2026

FairJourney Bio delivers antibody engineering for novel tumor-conditional IL-12 therapeutic approach that unlocks the potential of localized cytokine activation

FairJourney Bio ("FJBio"), a global antibody discovery expert, today announced the publication of a peer-reviewed study in mAbs describing a novel approach with the potential to improve the therapeutic window of IL-12, a potent anti-tumor cytokine.

From FairJourney Biologics 20 Aug 2026